Atara Biotherapeutics (ATRA) Equity Ratio (2022 - 2025)
Historic Equity Ratio for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to 1.21.
- Atara Biotherapeutics' Equity Ratio fell 9140.74% to 1.21 in Q3 2025 from the same period last year, while for Sep 2025 it was 1.21, marking a year-over-year decrease of 9140.74%. This contributed to the annual value of 0.89 for FY2024, which is 4872.41% down from last year.
- According to the latest figures from Q3 2025, Atara Biotherapeutics' Equity Ratio is 1.21, which was down 9140.74% from 0.95 recorded in Q2 2025.
- In the past 5 years, Atara Biotherapeutics' Equity Ratio ranged from a high of 0.59 in Q2 2022 and a low of 1.21 during Q3 2025
- Its 4-year average for Equity Ratio is 0.32, with a median of 0.59 in 2024.
- Its Equity Ratio has fluctuated over the past 5 years, first plummeted by 322526.96% in 2024, then plummeted by 45.21% in 2025.
- Quarter analysis of 4 years shows Atara Biotherapeutics' Equity Ratio stood at 0.34 in 2022, then plummeted by 278.21% to 0.6 in 2023, then plummeted by 48.72% to 0.89 in 2024, then crashed by 36.19% to 1.21 in 2025.
- Its Equity Ratio was 1.21 in Q3 2025, compared to 0.95 in Q2 2025 and 0.89 in Q1 2025.